Dave Sweeney
18 Dec 2015
Re: St James, Leeds Trial re your link which is impossible to date here are my thoughts and analysis[link] impossible to date that trial but the critical statement is Conclusion• Patch group shows reduced overall length of stay inhospital• No difference in critical care admission ratesNext steps: randomised controlled trial, cost analysis andpatient and staff satisfaction studies. We need to makesure that patients are happy with their care with the newmonitoring system.now the CURRENT trial is running in 2 hospitals commencing July so its a bit early to expect results as its being done over 6 months with a larger patient sample size - the Leeds one done by the same medical team is ALL about the metrics stated above[link] critical statement here is The trial is being led by Professor David Jayne, Professor of Surgery at St James’s, and will investigate the clinical benefits of the system, its health economic impact and the patients’ perspective. IN SUMMARY the link refers to OLD TRIALS and EVIDENCE and we still await the more comprehensive trial results and analysis from the current trials
gunnerbe
17 Dec 2015
St James, Leeds Trial I came across this but not sure whether this was a pre-trial or the initial results from the trial: [link] impressed
Solis
08 Dec 2015
Re: 2015 Market Assessment on Smart Patc... Good finds Mr. Google. Thanks
Mr Google
07 Dec 2015
Re: 2015 Market Assessment on Smart Patc... It's a bit of gamble selling or buying. Tempted to buy, but holding off until further announcement on Sensium.However, the appointment of Kevin Smith suggest there may be tweaks to the sensium business model. Looking at the table in the link in my earlier post, it suggests and I could be wrong that insurance companies will be funding the costs of patches in the US.
TheDrewster
07 Dec 2015
Re: 2015 Market Assessment on Smart Patches I too believe TMZ is (significantly) undervalued. I would however stop short of saying the company will not get cheaper still before equillibrium might be restored.Digital must surely be worth north or 3p, possibly 4?!But then, WTFDIK?
Mr Google
06 Dec 2015
2015 Market Assessment on Smart Patches Came across this link [link] is included and predicts the potential growth of the smart patches market.I believe Toumaz at the current market cap is undervalued.
Aaxb83
25 Nov 2015
Article on Health News [link] is a revolutionary new wireless early warning system utilizing radio waves and designed to improve patient outcomes and shorten hospital stays. The system, developed in the UK and introduced to the US market, enables early intervention by continuously and accurately monitoring vital signs of heart rate, respiration rate and axillary temperature every two minutes and alerting the nursing staff when pre-set thresholds are exceeded.According to a recent November 2015 ECRI report entitled: Top Ten Health Hazards for 2016, "Failure to effectively monitor postoperative patients for opioid-induced respiratory depression can lead to brain injury or death and was listed as number three on the list of hazards. Intermittent spot checks of oxygenation and ventilation every few hours are inadequate for reliably detecting opioid-induced respiratory depression."The system is based on a disposable, single-use, wearable patch that monitors patients outside of high acuity areas. notifying clinicians of changes in patients' vital signs, SensiumVitals brings the nurse to the deteriorating patient, allowing intervention before the condition worsens, potentially resulting in improved patient outcomes, shorter hospital stays, and lower treatment costs. It is currently in trials in two leading National Health Service (NHS) hospitals in the UK at St. James's University Hospital in Leeds and Queen Elizabeth Hospital in Birmingham.
Mr Google
17 Nov 2015
Re: TMZ Missed the bus? @strattyAgreed.It also increases awareness about wireless monitoring and its benefits.I have also come across this press release [link] the link it looks like Toumaz have setup an office in Boston MA and have a new COO Kevin Smith.Toumaz has the advantage of being FDA cleared and the US is a much bigger market.
stratty
17 Nov 2015
Re: TMZ Missed the bus? I don't think this is necessarily a bad thing. The market for these products is massive and this has just had a very positive review from the end users. it sounns like this is just a link between Aston University and the birminghams childrens home. lets see how Sensium is received at the Queen Elizabeth.
rollthediceagain
17 Nov 2015
TMZ Missed the bus? Article posted by Nod on Advfn[link] sp on it knees 2-2.25p has TMZ missed the health sensor bus with Keith Errey (ex-TMZ) now piloting their competitive product?
Mr Google
07 Nov 2015
Sotera Wireless - Gunner Trommer interview An interview with Gunner Trommer of Sotera Wireless.9 minutes into the interview, there is discussion on some of the barriers that Sotera are facing which are also applicable to Toumaz.[link] Health and Life Sciences General Manager Eric Dishman sits down with Gunnar Trommer, Ph. D., Vice President, Marketing and Business Development at Sotera Wireless, to discuss the company's new wearable form factor that measures vital signs and transmits the data wirelessly to a physician and into an EMR. The device is able to continuously monitor blood pressure readings and provide ICU-level diagnostics.Note that Intel are an investor in Sotera Wireless.
Aaxb83
06 Nov 2015
Worth a read Frontier Silicon, a digital radio technology business based in Cambridge UK, has been honoured by a world body after becoming the best-selling DAB solutions provider of all time. - See more at: [link]
Mr Google
03 Nov 2015
Surveillance Monitoring: An Emerging Standard of Care An interesting article worth a read by James Welch of Sotera Wireless. [link]
rollthediceagain
31 Oct 2015
Trouble at Toumaz II's choice of headings not mine ~ TMZ comments do little to inspire confidence.----[link] at ToumazRemotely monitoring the patient could become an enormous market, but it can take time to convince customers that it is effective and provides value for money as low-power, wireless semiconductor technologies developer Toumaz (TMZ) has found out. It has taken a lot longer than anticipated to commercialise its SensiumVitals technology. In the first half of 2015, revenues slumped from £509,000 to £237,000.SensiumVitals is an ultra-low power, wearable vital signs monitoring system with a battery that lasts for five days. It takes readings of the heart rate, respiration and temperature every two minutes.Trials in 2014 meant that Toumaz realised that it had to make the SensiumVitals product more robust and easier to use. Product development spending is focused on enhancing the technology in order to speed up its adoption.An indication of the disappointing progress made is that in the presentation for the 2013 results wireless healthcare was the first division covered. In the recent presentation for the 2015 interims digital audio was the first division covered and patient monitoring was second.Toumaz has regained the North American distribution rights to SensiumVitals and it is also focusing on the UK, France and Germany via direct sales teams and distributors. It has been estimated that the global market for wireless monitoring could be worth $1.5 billion a year, with North America accounting for 50% of the market.There are two NHS trials underway at St James’s University Hospital Leeds and Queen Elizabeth Hospital in Birmingham. St James’s is testing the system on the patients of colorectal wards, while Queen Elizabeth covers gastro-intestinal and liver wards. Both trials should be completed by next March.These trials, if successful, will provide data on how beneficial the system is. This will be published in peer-reviewed publications and should attract interest from other hospitals, which may want to integrate SensiumVitals into their systems.A review of the business model is underway. Toumaz has shown that its low-power wireless technology works and there is little competition in this area at the moment. The Toumaz share price has slumped over the past year and it needs to reduce its cash outflow.There is undoubtedly a large potential market for these cost-saving measures for hospitals, but Toumaz shows that progress for these businesses may not be smooth.
Mr Google
28 Oct 2015
Re: Jan Sensier Interview on BBC Breakfa... Your point about large companies actively developing remote monitoring systems is that their current solutions are primitive. They cannot move as quick as companies like Toumaz and rely on acquiring companies. To develop something from the patch, algorithms, to hubs, servers and then interface with hospitals EMR systems is a huge challenge for anyone entering this space including large companies.An example from Phillips[link] (missing heart rate and temperature monitor)I had a look at GE and Medtronic and I don't see much from them. They might be working on something in secret, but it may be some way off.Compare large company offerings with Toumaz, Isansys and Sotera and they have nothing that comes close to usable in a live hospital environment.Toumaz's main problem is that they are early and the market is immature and has yet to develop, but there is potential and whether Toumaz can execute is another matter.I don't think NHS is going to be their biggest market, it is going to be the US where this technology will help reduce re-admittance in hospitals as insurance companies do not pay for re-admittances when the first treatment failed. There mayl come a point in the US that insurance companies will mandate this type of technology as standard on condition of providing insurance cover to pay for treatments. It might be wise for Toumaz to target Insurance health providers to get their views.Risks remain and I do hope the review is complete soon.
